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Cancer metabolism, including in mitochondria, is a disease hallmark
and therapeutic target, but its regulation is poorly understood.
Here, we show that many human tumors have heterogeneous and
often reduced levels of Mic60, or Mitoﬁlin, an essential scaffold of
mitochondrial structure. Despite a catastrophic collapse of mitochondrial integrity, loss of bioenergetics, and oxidative damage,
tumors with Mic60 depletion slow down cell proliferation, evade
cell death, and activate a nuclear gene expression program of
innate immunity and cytokine/chemokine signaling. In turn, this
induces epithelial-mesenchymal transition (EMT), activates tumor
cell movements through exaggerated mitochondrial dynamics, and
promotes metastatic dissemination in vivo. In a small-molecule
drug screen, compensatory activation of stress response (GCN2)
and survival (Akt) signaling maintains the viability of Mic60-low
tumors and provides a selective therapeutic vulnerability. These
data demonstrate that acutely damaged, “ghost” mitochondria
drive tumor progression and expose an actionable therapeutic
target in metastasis-prone cancers.

mitophagy has been paradoxically linked to tumor progression
(14) as well as treatment resistance (15).
An important regulator of mitochondrial integrity is Mic60,
also called Mitofilin or inner membrane mitochondrial protein.
Mic60 is an essential constituent of a MICOS complex (16) that
maintains cristae architecture (17), organizes respiratory complexes (18), and ensures outer membrane biogenesis (19).
Whether this pathway is important in cancer has not been
determined, but there is evidence that Mic60 participates in
mitochondrial fitness, including PINK1/Parkin-directed mitophagy (20) and mitochondrial dynamics (21).
In this study, we investigated how mitochondrial fitness may
impact cancer traits and potentially expose therapeutic vulnerabilities in advanced disease.
Signiﬁcance
Exploitation of mitochondrial functions promotes tumor traits,
including metastasis, which is responsible for >90% of all cancer deaths. In this study, we investigated how mitochondrial
ﬁtness impacts tumor behavior. We found that acutely damaged, de-energized, and reactive oxygen species-producing
mitochondria not only persist in cancer but are also key enablers of metastasis. These “ghost” mitochondria originate from
the heterogeneous and often reduced expression of Mic60, an
essential scaffold of organelle structure, in certain human cancers. The compensatory activation of gene expression programs as well as GCN2/Akt kinase signaling enables the
survival of Mic60-low tumors but also provides a new therapeutic target in advanced and hard-to-treat malignancies.

mitochondria j cell motility j metastasis

T

he rewiring of metabolic pathways is a ubiquitous cancer
trait that confers cellular plasticity, expands clonal heterogeneity, and enables disease progression (1). There is now a
consensus that mitochondria are important for this process,
titrating energy output, buffering oxidative stress, and controlling a host of cell death programs (2). In particular, exploitation
of mitochondrial functions has been linked to metastatic competence (3, 4). This involves oxidative bioenergetics (5) and
redox balance (6) but also deregulated mitochondrial dynamics
(7), a process that controls the size, shape, and distribution of
mitochondria and their trafficking to the cortical cytoskeleton,
where they fuel pivotal steps of cell motility, such as membrane
lamellipodia dynamics, turnover of focal adhesion (FA) and
phosphorylation of signaling kinases (8).
However, the environment of tumor growth is highly unfavorable to mitochondrial fitness. Erratic oxygen concentrations,
high levels of oxidative radicals (9), constantly changing metabolic needs (10), and vulnerabilities of the mitochondrial proteome (11) are all potent stimuli to disrupt mitochondrial integrity,
shut off organelle functions, and activate cell death (12).
Quality-control measures activated in these settings, in particular
mitophagy (13), are designed to remove such subpar, “ghost”
mitochondria and restore homeostasis. However, the role of
these pathways in cancer is far from clear, and activation of
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Results

not reach statistical significance (SI Appendix, Fig. S1B). Heterogeneous Mic60 expression was also observed intratumorally.
When analyzed in patient samples of pancreatic ductal
adenocarcinoma (PDAC), Mic60 expression ranged from focal
perinuclear distribution in normal pancreatic acinar cells to disordered, submembranous or linear staining in in situ and invasive neoplastic epithelium to absence in poorly differentiated
(basaloid) carcinomas by IHC (Fig. 1C). Mechanistically, differentiation of patient-derived GBM neurospheres, a process
associated with the modulation of stemness and proliferative
potential (22), lowered Mic60 as well as HIF1α mRNA levels
(SI Appendix, Fig. S1D).

Mic60 Expression in Cancer. To study the role of mitochondrial
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fitness in cancer, we focused on Mic60 as an essential scaffold
of organelle integrity and function (18). Inspection of the
Human Protein Atlas database showed that Mic60 expression
was highly heterogeneous in cancer, as several tumor types had
reduced, increased, or unchanged levels of Mic60 compared to
normal tissues (SI Appendix, Fig. S1A). Immunohistochemical
(IHC) staining of a universal tumor microarray (TMA; n = 5 to
8 cases per tumor type) gave similar results (Fig. 1A), where
Mic60 expression was reduced in colorectal adenocarcinoma
(COREAD) and glioblastoma (GBM), unchanged in breast
(BRCA) and prostate adenocarcinoma (PRAD), or increased in
lung adenocarcinoma (LUAD) compared to adjacent normal tissue (SI Appendix, Fig. S1B). Consistent with these results, Mic60
mRNA levels in The Cancer Genome Atlas (TCGA) database
were reduced in GBM and COREAD but prominently upregulated in LUAD (SI Appendix, Fig. S1C). Other potential Mic60low tumors in this analysis included malignancies of kidney,
thyroid, head and neck, and soft tissue, whereas uterine and cervix cancer had higher Mic60 mRNA levels compared to normal
tissues (SI Appendix, Fig. S1C). Although breast cancer showed
increased Mic60 protein (SI Appendix, Fig. S1A) and mRNA (SI
Appendix, Fig. S1C) in public databases, our TMA analysis did
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Fig. 1. Mic60 expression in cancer. (A) A universal TMA was analyzed for differential expression of Mic60 in tumor vs. adjacent normal tissue by IHC. N,
normal; T, tumor. Cases of COREAD (n = 6N, 8T), GBM (n = 5N, 8T), BRCA (n = 5N, 8T), PRAD (n = 5N, 5T), and LUAD (n = 6N, 8T) were examined. Representative images are shown. Scale bars, low magniﬁcation, 6 mm; high magniﬁcation, 60 μm (×40). (B) Patient-derived tissue samples (#1 to #5) of GBM
(G) or disease-free margin (M) were analyzed by Western blotting. (C) Intratumoral heterogeneity of Mic60 expression in PDAC patients. Top Left, arrow,
perinuclear expression in normal acinar cells (×200); Top Right, perinuclear to diffuse cytoplasmic staining in nerves, smooth muscle, and ganglion cells
(arrow, ×200); Middle Left, apical cytoplasmic staining of high-grade pancreatic intraepithelial neoplasia (×400); Middle Right, faint perinuclear as well as
bright apical staining (arrow) of well-differentiated PDAC (×400); Bottom Left, asterisk, absent stain in high-grade basaloid PDAC, arrow (×200); Bottom
Right, transition between Mic60-positive well differentiated tumor (double arrows) and Mic60-negative high grade basaloid regions within the same
tumor gland (single arrow) (×400). (D) Mic60 interactome identiﬁed in PC3 cells by mass spectrometry. The fold vs. IgG condition, number of detected
peptides, and molecular weight (MW) are indicated. (E) PC3 cells transfected with control nontargeting siRNA (siCtrl) or Mic60-directed siRNA (siMic60)
were analyzed by transmission electron microscopy, and cristae length (mean ± SD) was quantiﬁed (n = 25). P < 0.0001. (F) PC3 cells as in E were analyzed
for mitochondrial outer membrane permeability by calcein staining and ﬂow cytometry. Numbers correspond to mean ﬂuorescence intensity (MFI; mean
± SD, n = 3). (G) PC3 cells as in E were analyzed for mitochondrial inner membrane potential by tetramethylrhodamine, ethyl ester (TMRE) staining and
ﬂow cytometry. MFI (mean ± SD) is shown (n = 3). P = 0.01.
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Requirement of Mic60 for Tumor Cell Proliferation. Based on these
results, we next asked if the loss of mitochondrial fitness induced
by Mic60 depletion affected tumor functions. Consistent with
DNA damage (SI Appendix, Fig. S3 C and D), Mic60-depleted cells
exhibited slower cell cycle progression (Fig. 2A) and accumulation
of cells with G2/M DNA content throughout a 7-d culture (Fig.
2B). This resulted in a reduced proliferation of normal and tumor
cell types (Fig. 2C and SI Appendix, Fig. S4A), as well as an inhibition of colony formation (Fig. 2D). An analysis of the DepMap
Portal (23) revealed dependency scores < 1 for all tumor types
examined after Mic60 silencing by RNA interference (RNAi) or
CRISPR-Cas9 (Fig. 2E and SI Appendix, Fig. S4B), consistent with
a general requirement of Mic60 for tumor cell proliferation.
Accordingly, PC3 clones with reduced Mic60 levels by shRNA or
CRISPR-Cas9 formed slow-growing superficial tumors in immunocompromised mice (Fig. 2F) with decreased Ki-67 reactivity (SI
Appendix, Fig. S4C), a marker of cell proliferation. Conversely,
control PC3 cells formed exponentially growing flank tumors (Fig.
2F) with high Ki-67 staining (SI Appendix, Fig. S4C).
Despite cellular damage and activation of mitophagy, tumor
cells with reduced Mic60 did not upregulate ferroptosisassociated genes (SI Appendix, Fig. S4D), a type of cell death
induced by mitochondrial stress, and oxidized lipid content, a
marker of ferroptosis, was unchanged compared to control cultures (Fig. 2G). Similarly, Mic60 depletion only modestly affected
mitochondrial apoptosis, as quantified by caspase (DEVDase)
activity (Fig. 2H) or hypodiploid DNA content and flow cytometry (SI Appendix, Fig. S4E). Finally, no significant differences in
necroptotic cell death were observed in control or Mic60-silenced
cells over a 3-d (Fig. 2I) or 5-d culture (SI Appendix, Fig. S4F), by
analysis of plasma membrane integrity and light microscopy.
Ghosh et al.
Ghost mitochondria drive metastasis through adaptive GCN2/Akt
therapeutic vulnerability

Mic60 Depletion Induces a Unique Innate Immunity and Cytokine/
Chemokine Gene Signature. Next, we looked at potential mecha-

nisms of cellular adaptation in Mic60-low tumors. By RNA
sequencing (RNA-Seq), Mic60 silencing induced unique transcriptional changes in PC3 cells with upregulation of a type I
interferon (IFN) response and cytokines/chemokines reminiscent
of a senescence-associated secretory phenotype (SASP) (Fig. 3A)
(24). The Mic60 transcriptome activated in these settings also
comprised PI3K/Akt signaling (see below) as well as pathways of
genomic integrity (NER), endoplasmic reticulum stress, unfolded
protein response (UPR), pattern recognition (RIG-1), and cytoskeletal (ARP-WASP) remodeling (Fig. 3B). In contrast, Mic60
depletion suppressed eIF2α signaling (Fig. 3B and see below).
In validation experiments, Mic60-depleted cells upregulated
SASP-like cytokines (IL6, IL8, IL18, and IL1α), chemokines
(CXCL2, CXCL3), protease (MMP13), and growth factor modulators (IGFBP7, IGFBP3) (SI Appendix, Fig. S5A), as well as
effectors of IFN signaling, IFIT1, IFIT3, MX1, OAS1, ISG15,
and IFITM1 (SI Appendix, Fig. S5B) by RT-PCR. IL23 and
MMP1 were not affected (SI Appendix, Fig. S5A). Similar
results were obtained at the protein level, as Mic60 silencing
increased the expression of MX2 and MMP13 by Western blotting (SI Appendix, Fig. S5C) and heightened the release of cytokines (IL6, IL8, CXCL10), protease (MMP13), and IFNs
(IFNα and IFNβ) in the cell supernatant compared to control
transfectants (SI Appendix, Fig. S5D). Finally, TCGA analysis
demonstrated that all 52 IFN/SASP-like genes of the Mic60
transcriptome were significantly upregulated in Mic60-low
tumors of the head and neck, brain (GBM), colon, rectum, kidney, and thyroid compared to normal tissues (Fig. 3C).
Mechanistically, siRNA silencing of STING (SI Appendix,
Fig. S5E), a key regulator of mitochondrion-directed innate
immunity, abolished the increase in cytokine mRNA levels after
Mic60 loss (Fig. 3D). In addition, Mic60 depletion was accompanied by an increased phosphorylation of STAT1 (Ser727) and
extracellular release of HMGB1 (SI Appendix, Fig. S5F), which
are two effectors of IFN signaling. In contrast, senescenceassociated β-galactosidase staining was unchanged in control or
Mic60-depleted cultures (Fig. 3E).
Mic60 Regulation of Tumor Cell Invasion and Metastasis. SASP signaling has been associated with increased tumor cell invasion and
metastasis (25). Accordingly, Mic60 depletion changed the morphology of PC3 cells to a flattened, elongated, and spindle-shaped
appearance, characterized by rearrangement of the actin cytoskeleton and redistribution of mitochondria to the cortical cytoskeleton (Fig. 4A). This was associated with reduced cellular
roundness, increased surface area (Fig. 4B), and the appearance
of epithelial-mesenchymal transition (EMT) markers, including
E- and N-cadherin switch, and upregulation of vimentin, SLUG,
and SNAIL (Fig. 4C). Functionally, Mic60 depletion enhanced
FA turnover (SI Appendix, Fig. S6A), increasing the fraction of
new and decayed FA, while reducing stable FA (SI Appendix, Fig.
S6B). This resulted in a greater speed of single-cell movements,
longer distance traveled by individual cells (Fig. 4D), and accelerated directional cell motility in a “wound” closure assay, shortening the half-time (t1/2) of wound closure from 16.3 h to 6.3 h (SI
Appendix, Fig. S6 C and D). In addition, silencing of Mic60
increased tumor cell invasion across Matrigel (Fig. 4E and SI
Appendix, Fig. S6E), whereas re-expression of Mic60 complementary DNA (cDNA) in these settings normalized Matrigel invasion
(Fig. 4F). As for signaling requirements, Mic60 silencing
increased the phosphorylation of Focal Adhesion Kinase (FAK)
(SI Appendix, Fig. S6F), and FAK targeting by siRNA (SI
Appendix, Fig. S6G) or a small-molecule inhibitor (FAKi) normalized FA dynamics (SI Appendix, Fig. S6B) and restored the singlecell motility of PC3 (SI Appendix, Fig. S6 H and I) or LN229 (SI
Appendix, Fig. S6 J and K) cells to levels of control transfectants.
PNAS j 3 of 9
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(shRNA) or CRISPR-Cas9 (SI Appendix, Fig. S2A, Top). Small
interfering RNA (siRNA) sequences targeting Mic60 were also
characterized in PC3 cells, normal diploid fibroblasts, MRC5,
breast adenocarcinoma MDA231, and osteosarcoma HT1080
cells (SI Appendix, Fig. S2A, Bottom).
Using these approaches, silencing of Mic60 caused a catastrophic collapse of mitochondrial integrity in tumor cells, with
disassembly of tubular network and cristae organization (Fig.
1E). This was accompanied by acute mitochondrial damage,
characterized by increased outer membrane permeability (Fig.
1F) and depolarization of the inner membrane (Fig. 1G and SI
Appendix, Fig. S2B). As a result, Mic60-depleted tumor cells
exhibited decreased oxygen consumption rates (SI Appendix, Fig.
S2C), with lower basal and maximal respiration (SI Appendix,
Fig. S2D), reduced adenosine triphosphate (ATP) production
(SI Appendix, Fig. S2 E and F), and increased phosphorylation
of AMPK, a marker of cellular starvation (SI Appendix, Fig.
S2G). Despite a modest increase in antioxidant glutathione
(GSH), these cells showed acute oxidative stress with a
decreased GSH:glutathione disulfide (GSSG) ratio (SI
Appendix, Fig. S3A), heightened production of total and mitochondrial reactive oxygen species (ROS) (SI Appendix, Fig.
S3B), and increased expression of γH2AX (SI Appendix, Fig.
S3C), as well as formation of subnuclear γH2AX foci (SI
Appendix, Fig. S3D). Consistent with loss of mitochondrial integrity, Mic60-low tumor cells activated quality-control mechanisms
of autophagy with punctate GFP-LC3 staining (SI Appendix, Fig.
S3E), processing of LC3 to a lipidated form, and upregulation of
p62, i.e., sequestosome (SI Appendix, Fig. S3F). Mitophagy was
also induced in these settings, as judged by increased MitoKeima
red fluorescence reporter activity (SI Appendix, Fig. S3G), loss
of mitochondrial mass (SI Appendix, Fig. S3H), and degradation
of mitochondrial outer membrane proteins (SI Appendix, Fig.
S3I). Silencing of p62 was insufficient to restore outer membrane
proteins or mitochondrial mass after Mic60 depletion.
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Fig. 2. Requirement of Mic60 for tumor cell proliferation. (A) PC3 cells transduced with pLKO or shMic60 were labeled with CellTrace violet and analyzed
by ﬂow cytometry. The MFI of three independent experiments (mean ± SD) are shown. (B) PC3 cells transfected with siCtrl or siMic60 were analyzed by
propidium iodide (PI) staining and ﬂow cytometry after 7 d. The percentage of cells in the various cell cycle phases (mean ± SD) is shown (n = 4). (C) PC3
(Top) or PRAD DU145 (Bottom) cells as in B were analyzed for cell proliferation by direct cell counting at the indicated time intervals. Mean ± SD (n = 4
to 5). PC3, *P = 0.02; **P = 0.008. DU145, *P = 0.01 to 0.02; ***P = 0.0001. ns, not signiﬁcant. (D) PC3 cells as in A were analyzed for colony formation
(mean ± SD) by crystal violet staining and light microscopy. Representative images are shown (n = 6). P < 0.0001. (E) DepMap Project analysis of the effect
of Mic60 depletion by RNAi or CRISPR on tumor cell proliferation. (F) PC3 cells as in A (Top) or wild-type (WT) or Mic60 knockout (KO) PC3 cells (Bottom)
were injected subcutaneously in immunocompromised NSG mice and ﬂank tumor growth was quantiﬁed at the indicated time intervals. Each line corresponds to an individual tumor. The mean ± SD of tumor growth (mm3) at d 35 is indicated (n = 6 to 8). P < 0.0001. (G) PC3 cells transfected with siCtrl or
siMic60 were labeled for oxidized lipids (Bodipy) and analyzed after 72 h (Top) or 96 h (Bottom) by ﬂow cytometry. MFIs of a representative experiment
are indicated (n = 3). Gray shades, unstained cells. (H) PC3 cells as in G were analyzed for DEVDase activity/PI staining by multiparametric ﬂow cytometry.
The percentage of cells (mean ± SD) in early (Bottom right) or late (Top right) apoptosis are indicated (n = 3). (I) PC3 cells as in G were analyzed for cell
death at the indicated time intervals by Trypan blue exclusion and direct cell counting. Mean ± SD (n = 2 to 3).

Although impaired in primary tumor growth (Fig. 2F), superficial flank tumors of Mic60-depleted PC3 cells gave rise to
increased metastatic dissemination to the lungs of immunocompromised mice (Fig. 4G). As a second, independent model of
metastasis, we injected control or Mic60-depleted PC3 cells in the
spleen of immunocompromised animals and looked at liver
metastasis after 11 d. Here, Mic60-silenced PC3 cells generated
more numerous and larger liver metastases compared to controls
(Fig. 4 H and I). Based on these data, we next looked at matched
patient samples of primary and metastatic LUAD. In this comparison, Mic60 mRNA levels increased in metastases compared to
the primary tumor (Fig. 4J, Top) and the nonneoplastic lung tissue
(Fig. 4J, Bottom), suggesting that Mic60 becomes re-expressed at
established metastatic sites to support tumor cell proliferation.
Regulation of Mitochondrial Dynamics and Cell Movements by
Mic60. The mechanism(s) underlying increased tumor cell

motility after Mic60 targeting were next investigated. Despite
the loss of mitochondrial fitness, Mic60 depletion stimulated
mitochondrial dynamics in LN229 cells (SI Appendix, Fig. S7 A
and B) and less consistently in other tumor types, resulting in
higher rates of mitochondrial fission (SI Appendix, Fig. S7C).
Mitochondrial fusion was less affected (SI Appendix, Fig. S7 B
and C). As a result, Mic60-depleted cells exhibited heightened
subcellular mitochondrial trafficking, with a longer distance
4 of 9 j PNAS
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traveled by individual mitochondria (SI Appendix, Fig. S7D)
and increased accumulation of mitochondria at the cortical
cytoskeleton of LN229 and PC3 cells compared to controls (SI
Appendix, Fig. S7 E and F).
Mechanistically, siRNA silencing of mitochondrial GTPase
RHOT1 or RHOT2 (SI Appendix, Fig. S8A), which mediate
mitochondrial trafficking in tumors (26), normalized the speed
of mitochondrial movements and the distance traveled by individual mitochondria after Mic60 depletion (SI Appendix, Fig.
S8B). Buffering oxidative stress gave similar results, as the
reconstitution of Mic60-silenced cells with antioxidant Prx3
(27) corrected the increase in single-cell motility (SI Appendix,
Fig. S8C), lowered the speed of cell movements and the total
distance traveled by individual cells to levels of control cultures
(SI Appendix, Fig. S8D), and reversed the increase in Matrigel
invasion in these settings (SI Appendix, Fig. S8E). Reconstitution of Mic60-silenced cells with a mitochondrial-targeted
superoxide scavenger, MitoTempo, also normalized tumor cell
invasion to control levels (SI Appendix, Fig. S8F).
Adaptive GCN2-Akt Signaling as Therapeutic Vulnerability in Mic60low Tumors. Finally, we asked if adaptive mechanisms activated

in Mic60-low tumors exposed actionable therapeutic vulnerabilities. In a small-molecule drug screen, antagonists of Akt
(Akt inhibitor VIII) or General Control Nonderepressible 2
Ghosh et al.
Ghost mitochondria drive metastasis through adaptive GCN2/Akt
therapeutic vulnerability

% Genes

10
80 -log10 FDR
40

62%

0 SASP

siCtrl

4.1-fold
p=10-9
15%

nonSASP
siMic60

3
2
1
0

D
0.04

0
0.15

IFIT2 0.04

IL6

0
IFNα 0.08

IFNβ

0
0
siCtrl + - + + - + - + - +
siSTING - + - +
pLKO shMic60 pLKO shMic60

Fig. 3. A Mic60 transcriptome in cancer. (A) PC3 cells transfected with siCtrl or siMic60 were analyzed by RNA-Seq, and relative fold changes in gene
expression (false discovery rate [FDR] < 5%) were visualized in a heatmap. (B) Enrichment analysis of genes signiﬁcantly different (FDR < 5%) between
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kinase GCN2 (GCN2-IN-1) killed Mic60-silenced PC3 cells
more efficiently than control cultures (Fig. 5 A and B). Natural
compounds, podophyllotoxin and curcumin, p53 reactivator
NSC319726, Bcl2 pathway inhibitor, Navitoclax, P glycoprotein
antagonist, Tariquidar, multi-CDK inhibitor, NVP-LCQ195 and
histone lysine-specific demethylase-1 inhibitor, and SP2509 also
showed preferential killing against Mic60-low PC3 cells (Fig.
5B). Consistent with these data, Mic60 silencing increased Akt
phosphorylation (SI Appendix, Fig. S9A), with downstream activation of Akt targets PDK1, BAD, p70S6K, and p27 quantified
in a phosphoarray screen (SI Appendix, Fig. S9 B and C). Functionally, treatment with Akt inhibitor VIII or another small
molecule Akt antagonist, MK2206, suppressed proliferation
selectively of Mic60-depleted PC3 cells compared to control
transfectants (SI Appendix, Fig. S9D).
GCN2 is a critical eIF2α kinase in the integrated stress
response (ISR). Accordingly, ISR effectors ATF4, ATF6,
eIF2AK3, and calreticulin were selectively upregulated after
Mic60 depletion by RNA-Seq analysis (Fig. 5C). This was
accompanied by an increased expression of ATF4 and ATF6 by
Western blotting (Fig. 5D) and translocation of transcriptionally
active ATF4 to the nucleus of Mic60-low PC3 cells compared to
parental cultures (Fig. 5E). Consistent with these data, Mic60
silencing induced a strong phosphorylation of eIF2α in PC3 cells,
whereas total eIF2α was unaffected (Fig. 5D). Bioinformatics
analysis of the Ivy Glioblastoma Atlas Project (https://
glioblastoma.alleninstitute.org) demonstrated that ISR regulators EIF2AK2, EIF2A, ATF4, XBP1, and DDIT3 were differentially increased in Mic60-low GBM and spatially localized within
“pseudopalisades,” which are hypoxic hypercellular structures
associated with greater invasiveness (Fig. 5F). Furthermore, high
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levels of ISR effectors DDIT3 and ATF4 correlated with shortened patient survival in Mic60-low GBM and kidney cancer
(Fig. 5G) but not Mic60-high BRCA and LUAD (SI Appendix,
Fig. S9E). Functionally, a small-molecule GCN2 inhibitor
(GCN2-IN-1) inhibited proliferation (pLKO, 3.3 × 105 ± 0.62 ×
105 cells; shMic60, 1.95 × 105 ± 0.4 × 105 cells; P = 0.009) and
activated Annexin V-associated apoptosis (Fig. 5H) and caspasedependent cell death (pLKO, 8.4 ± 6.3%; shMic60, 23.1 ± 5.6%;
P = 0.04) preferentially in Mic60-silenced PC3 cells compared to
control cultures. As an independent approach, siRNA silencing
of GCN2 (SI Appendix, Fig. S9F) also increased cell death selectively in Mic60-silenced cultures (SI Appendix, Fig. S9G).
Discussion
In this study, we have shown that Mic60, an essential scaffold
of mitochondrial structure, is heterogeneously expressed and
often reduced in human cancer compared to normal tissues. As
modeled in tumor cell lines, even a partial reduction in Mic60
levels was sufficient to induce an acute loss of mitochondrial fitness, leading to bioenergetics defects, cellular starvation, and
oxidative stress. Despite the activation of quality-control measures of autophagy and mitophagy, tumor cells harboring such
extensively damaged, ghost mitochondria managed to evade
cell death, slowed down cell proliferation, and activated mitochondrial dynamics to fuel increased cell invasion and metastasis. This response was accompanied by the expression of an
IFN/SASP-like transcriptome, as well as adaptive activation of
GCN2/Akt survival signaling, which provided an actionable
therapeutic target in these metastasis-prone tumors.
The basis for the heterogeneous expression of Mic60 in cancer remains to be elucidated. This may result from mitochondrial
PNAS j 5 of 9
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and/or environmental stress conditions associated with tumor
growth, including defective oxidative phosphorylation (28), or
alternatively, mechanisms of tumor evolution, as suggested here
by Mic60 downregulation during differentiation of patientderived GBM neurospheres.
Irrespectively, decreased Mic60 levels generate subpar, ghost
mitochondria that bear striking similarities to the mitochondrial
defects seen in aging (29). Consistent with this parallel, in vivo
models of aging have been associated with reduced Mic60
levels (30), heightened SASP signaling (31), mitochondria-tonuclei retrograde gene expression (32), and a general, proinflammatory environment (33). However, key differences
between aged and Mic60-low mitochondria were also noted
(31). Aside from distinct profiles of cytokine induction, Mic60depleted tumor cells were negative for senescence-associated
β-galactosidase and did not undergo permanent G1 cell cycle
arrest, and gene expression changes in these settings were unrelated to p53 status.
A unique adaptive response of Mic60-low tumors was the
upregulation of a nuclear transcriptome combining a type I
IFN response characteristic of innate immunity (34) and cytokines/chemokines reminiscent of SASP signaling (25). Mechanistically, mitochondrial stressors induced by Mic60 loss, such
as ROS (35), loss of membrane integrity (36), and energy
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starvation (37), have all been associated with mitochondria-tonuclei retrograde gene expression (38). Activation of a type I
IFN response in these settings fits well with a key role of mitochondria in innate immunity (39), in line with the activation of
STAT1 and the requirement of STING for cytokine production
observed here. While there is evidence that SASP-associated
cytokine/chemokine signaling promotes tumor growth, favors an
immunosuppressive microenvironment, and enhances metastasis
(25), the role of a type I IFN response in cancer is likely timeand context-specific. Whereas acute IFN signaling has been associated with antitumor immunity and improved treatment
responses (34), sustained inflammatory conditions are protumorigenic (40) and chronic IFN stimulation enables myeloiddirected immunosuppression (41) and propagation of cancer
stemness (42).
Consistent with this scenario, Mic60-low tumors switched
from a proliferative to a highly motile and prometastatic phenotype, contributed by EMT, sustained FAK phosphorylation, and
heightened mitochondrial dynamics (8). Described as phenotype switching (43), this reversible transition between proliferative and migratory states has been proposed as a potential
escape mechanism for tumor cells to leave a stress-laden, unfavorable microenvironment and colonize distant sites, i.e.,
metastasis (44). Regulators of mitochondrial dynamics, such as
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syntaphilin (27), FUNDC1 (45), and now Mic60 depletion (this
study), are important mediators of phenotype switching,
reprogramming oxidative bioenergetics, and redox balance to
promote heightened cell migration and invasion at the expense
of cell proliferation. Consistent with this model, oxidative stress
generated in Mic60-low tumors was a key mediator of increased
mitochondrial trafficking and tumor cell movements, in keeping
with a central role of ROS in tumor cell motility (46), EMT,
and metastasis (47).
Despite an extensive loss of mitochondrial fitness, activation
of autophagy/mitophagy, and high ROS production, Mic60-low
tumor cells managed to persist likely through the activation of
compensatory cell survival mechanisms. The induction of
GCN2/ISR as well as Akt signaling (48, 49) observed in these
settings appears ideally poised to adjust metabolism under
stress (50, 51), preserve mitochondrial integrity (22, 52) and
oppose cell death (53, 54). Although correlating with shortened
patient survival, a potential dependence of Mic60-low tumors
to GCN2/ISR/Akt adaptive signaling was therapeutically
exploitable, and proof-of-concept studies shown here demonstrated that pharmacologic or genetic targeting of this pathway
can restore mitochondrial cell death and inhibit proliferation
selectively of Mic60-low tumor cells.
In summary, we have shown that persistent, acutely degraded
ghost mitochondria are major signaling hubs in cancer, driving
multiple, adaptive responses of nuclear gene expression, ISR
activation, and suppression of mitochondrial cell death to enable
metastatic competence. This reinforces the role of mitochondrial
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reprogramming as an important therapeutic target in cancer
(55), especially in hard-to-treat and metastasis-prone malignancies with currently limited therapeutic options.
Materials and Methods
Patient Samples. Primary patient samples arranged in a universal TMA were
examined for differential Mic60 expression by IHC, as described (56). Archival
tissues and clinical records were obtained from Fondazione Istituto di Ricovero
e Cura a Carattere Scientiﬁco (IRCCS) Ca’ Granda Hospital in Milan, Italy, under
a protocol approved by the Institutional Review Boards (IRBs) of Fondazione
IRCCS Ca’ Granda-Ospedale Maggiore Policlinico (code 179/2013). Because of
the retrospective nature of this study and the use of data anonymization practices, the need for written informed consent was waived. For the glioma
series, fresh-frozen material was available from Fondazione IRCCS Ca’ Granda
Hospital under IRB protocol 275/2013, and written informed consent from all
patients was obtained before surgery. Clinically annotated patient samples
with a conﬁrmed histologic diagnosis of PDAC (n = 5) were obtained from the
archival database of the Department of Pathology at Yale New Haven Hospital upon approval from the Yale University IRB and examined for intratumoral
heterogeneity of Mic60 expression by IHC.
Proteomics. Immune complexes of Mic60 or nonbinding immunoglobulin G
(IgG) were precipitated from PC3 cells and separated by sodium dodecyl sulphate gel electrophoresis for ∼5 mm followed by ﬁxing and staining with
colloidal Coomassie. The region of the gel-containing proteins was excised
and digested with trypsin. Tryptic peptides were analyzed by liquid
chromatography-tandem mass spectrometry (LC-MS/MS) on a Q Exactive highﬁeld (HF) mass spectrometer (Thermo Scientiﬁc) coupled with a NanoACQUITY ultra performance liquid chromatography (UPLC) system (Waters).
Samples were injected onto a UPLC Symmetry trap column (180-μm inner
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diameter [i.d.] × 2 cm packed with 5-μm C18 resin; Waters), and tryptic peptides were separated by RP-HPLC on a BEH C18 nanocapillary analytical column
(75-μm i.d. × 25 cm, 1.7-μm particle size; Waters) using a 90-min gradient. Eluted
peptides were analyzed in data-dependent mode where the mass spectrometer
obtained full MS scans from 400 to 2,000 m/z at 60,000 resolution. Full scans
were followed by MS/MS scans at 15,000 resolution on the 20 most abundant
ions. Peptide match was set as preferred, and the exclude isotopes option and
charge-state screening were enabled to reject singly and unassigned charged
ions. MS/MS spectra were searched using MaxQuant 1.6.5.0 (57) against the UniProt human protein database (October 2017). MS/MS spectra were searched
using full tryptic speciﬁcity with up to two missed cleavages, static carbamidomethylation of Cys, variable oxidation of Met, and variable protein N-terminal
acetylation. Consensus identiﬁcation lists were generated with false discovery
rates of 1% at protein and peptide levels. Undetected protein intensity values
of 0 were ﬂoored to the value of 106 (minimum nonzero detected intensity was
1,233,300), and a total of 1,534 detected proteins were taken for further annotation analysis. Proteins were then annotated as mitochondrial related using
the MitoCarta 2.0 database, and 119 mitochondrial proteins detected with at
least 5 peptides at an intensity over 10-fold versus IgG control were considered
as Mic60-associated proteins.

Small-Molecule Drug Screening. Cell viability screening against the MedChem
Express anti-cancer library (1,820 compounds) was performed using CellTiterGlo (Promega). PC3 cells stably transduced with pLKO or Mic60-directed
shRNA (shMic60) were maintained in complete media, trypsinized, and plated
(500 cells/well) in 40 μL of complete medium the day before the experiment in
white, clear-bottom 384-well plates. A total of 50 nL of test compound was
added to each well using the Janus MDT Nanohead (Perkin-Elmer). Each compound was screened at a ﬁnal concentration of 10, 1, 0.1, and 0.01 μM. After a
72-h incubation at 37 °C in the presence of 5% CO2, 20 μL of the CellTiterGlo
reagent was added to each well. After 15 min, luminescence was measured
using the Envision Multimode plate reader (PerkinElmer). The raw data were
normalized to % inhibition, where 0% is the relative light units (RLU) in the
presence of dimethylsulfoxide, and 100% is the RLU in the presence of 1 μM
bortezomib. Estimated half maximal inhibitory concentration (IC50) values for
each compound were determined using nonlinear regression ﬁts on the data
to a one-site binding model in XlFit (ID Business Solutions Ltd. [IDBS]). Because
only 4 data points were used in this calculation, the top and bottom of the
curve was ﬁxed to 100% and 0%, respectively, with a constant slope value
of 1.

Mitochondrial Time-Lapse Videomicroscopy. Cells (2 × 104) growing on high
optical quality glass-bottom 35-mm plates (MatTek Corporation) were incubated with 100 nM Mitotracker Deep Red FM dye for 1 h and imaged on a
Leica TCS SP8 × inverted laser scanning confocal microscope using a 63×
1.40NA oil objective as described (58).

Statistical Analysis. Data are expressed as mean ± SEM or mean ± SD of
multiple independent experiments or replicates of representative experiments out of a minimum of two or three independent determinations.
Two-tailed Student’s t test or Wilcoxon rank sum test was used for twogroup comparative analyses. For multiple-group comparisons, ANOVA or
Kruskal–Wallis test with post hoc Bonferroni’s procedure were applied. All
statistical analyses and graphing were performed using GraphPad software package (Prism 9.0) for Windows. A P value of <0.05 was considered
statistically signiﬁcant.

Single-Cell Motility. Cells (2 × 104) were seeded in 4-well Ph+ Chambers (Ibidi)
in complete growth medium and allowed to attach for 16 h at 37 °C. Timelapse videomicroscopy was performed over 10 h, with a time-lapse interval of
10 min. Stacks were imported into Image J Fiji software for analysis, and at
least 10 to 20 cells per condition were tracked using the Manual Tracking plugin for Image J Fiji. Tracking data were exported into the Chemotaxis and
Migration Tool v. 2.0 (Ibidi) for graphing and calculation of the mean and SD
of speed and accumulated distance of movement. For directional cell migration, wounds were made in monolayers of PC3 cells using a 10-μL pipette tip.
Cell debris were washed off, and cultures were maintained in complete
growth medium containing 10% fetal bovine serum at 37 °C and 5% CO2.
Time-lapse imaging of migrating cells was performed using a TE300 inverted
microscope (Nikon) equipped with an incubator set at 37 °C, 5% CO2, and
95% relative humidity. Each image was acquired using a 10× objective of the
same ﬁelds at each 10-min interval for a total of 24 h.
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